Roche Signs First In-licensing Deal In Korea With DigitalBiotech For Alzheimer's Disease Candidate
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's DigitalBiotech signed a research collaboration and license option agreement with Roche covering DigitalBiotech's proprietary RAGE antagonist program targeting Alzheimer's disease
You may also be interested in...
Stimulus Plans For Japan's Life Sciences Industries May Not Address Main Challenge - Bio Japan Conference
YOKOHAMA, Japan - Government agencies will initiate a plan in June 2011 to jumpstart Japan's lagging bioventure market, but government officials seem wary about being able to transform Japan's venture culture, a necessity for funding Japan's innovative technologies and medicines
Stimulus Plans For Japan's Life Sciences Industries May Not Address Main Challenge - Bio Japan Conference
YOKOHAMA, Japan - Government agencies will initiate a plan in June 2011 to jumpstart Japan's lagging bioventure market, but government officials seem wary about being able to transform Japan's venture culture, a necessity for funding Japan's innovative technologies and medicines
Asia Spotlight: Roche's Joe McCracken On Early-stage Partnering In Asia
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at 1http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.